Health Impact Report - Biotechnology & Pharmaceuticals Edition

In our latest quarterly review of corporate sustainability impacts, risks and opportunities, we find that biotechnology and pharmaceutical companies have made substantial ESG commitments, with Johnson & Johnson achieving carbon neutrality at 35 sites through onsite renewables and efficiency upgrades, avoiding 350,000 tonnes CO₂e in 2023. The report highlights how AstraZeneca expanded its Health Care Access Index to 42 LMICs, benefiting 40 million people through discounted oncology therapies, while addressing both financial materiality and impact materiality considerations for pharmaceutical ingredients across global value chains.

This report analyses thousands of sustainability disclosures from 20 leading entities in the industry, including Johnson & Johnson, Roche Holding and Pfizer. Published in Q225 as part of a quarterly series, it also includes disclosures from Global South entities like Aspen Pharmacare, Biocon and Dr. Reddy's Laboratories. The global nature of this analysis makes it an ideal source of external evidence for sustainability accounting and disclosure, particularly for organisations implementing blockchain tracking for clinical trial suppliers and aligning ESG targets with executive incentives.